Beijing Aotter Shu'er Health Products Development Co., Ltd.
Beijing Aotshuer Health Products Development Co., Ltd. (hereinafter referred to as "Aobao"), established in 2000, is a wholly-owned subsidiary of Bishengyuan Holdings Co., Ltd., headquartered in Linglong Tiandi Bishengyuan Building on the North Road, West Fourth Ring Road, Haidian District, Beijing. Its production base is located in Fangshan Qiushi Industrial Park, covering an area of 228 acres, and has 18 imported IMA high-speed tea bag packaging machines from Italy. It is a company integrating R&D, production and sales, and focuses on production and management of Chinese health care functions. Advanced tea enterprise. Since its establishment, the company has developed rapidly with the concept of upright management and pragmatic management, and its business scale has continued to grow, and has obtained the export certification qualification of the health care product industry. Bishengyuan Holdings Co., Ltd. and its subsidiaries (collectively referred to as "Bishengyuan" or "Group") are high-quality suppliers of functional health tea in China, mainly engaged in the research, development, production, sales and promotion of functional health tea and medicines. For twenty years, the group has produced Bishengyuan brand Changrun Tea and Bishengyuan brand Changjing Tea (collectively known as "two teas") in accordance with the concept of "herbal health and functional teas". In recent years, the group has continued to deepen its business in the two teas and has successively launched a series of functional tea products such as Bishengyuan brand filamentary tea (collectively known as "three teas" with the two teas). The Group has started selling Laili brand Orlistat weight loss capsules since April 2015, and has been through its subsidiary Zhongshan Wanhan Pharmaceutical Co., Ltd. ("Zhongshan Wanhan") and Zhongshan Wanhan Yuanxin Pharmaceutical Research and Development Co., Ltd. ("Zhongshan Wanyuan", collectively known as "Zhongshan Wanhan Wanyuan"), develops, produces and sells Bishengyuan brand Orlistat weight loss capsules. The group's product layout extends from the weight loss health tea market to the over-the-counter drug ("OTC") market, further covering the weight loss market sector. Since its launch, Bishengyuan brand Orlistat weight loss capsules have been well received by consumers. The Group's San Tea Production Base is located in Fangshan District, Beijing. The factory and production process meet the national GMP standards. The San Tea Products have passed ISO9001, ISO22000, and HACCP system certification. The packaging equipment is a C24 type tea bag high-speed machine introduced by IMA, Italy. It is specially designed for "cotton thread sailor knot connecting tea bags and hanging tags". The inner and outer bags are formed at one time and the bag making process is automatically completed. The production workshop is fully enclosed, and the pelletizing workshop and the inner packaging workshop are clean areas of 100,000 yuan, and are temperature and humidity monitoring. The overall plan of the factory is a garden-style factory with a beautiful environment and the sanitation, technology, process, and management are all at the advanced level of the industry. The three teas in the Group are all made of natural Chinese herbal medicines and tea as raw materials, and are scientifically developed, formulated and produced. They are in need of intestinal moistening and laxative and weight management, or have been slightly disturbed in health and quality of life. Those who provide safe, effective, convenient and affordable health care products. On September 29, 2010, Bishengyuan Holdings Co., Ltd. was officially listed on the main board of the Hong Kong Stock Exchange with the stock code HK00926, marking a historic step for Bishengyuan to achieve the integration of corporate development with the international capital market. In the future, the Group will continue to deepen its development in the big health industry, and build industrial cooperation and incubation mechanisms based on the fields of "weight loss and weight management" and "intestinal moistening and laxative and gastrointestinal health", improve the industrial chain, and strive to build a big health industry. Ecological system.
Beijing Aotter Shu'er Health Products Development Co., Ltd.
Beijing Aotshuer Health Products Development Co., Ltd. (hereinafter referred to as "Aobao"), established in 2000, is a wholly-owned subsidiary of Bishengyuan Holdings Co., Ltd., headquartered in Linglong Tiandi Bishengyuan Building on the North Road, West Fourth Ring Road, Haidian District, Beijing. Its production base is located in Fangshan Qiushi Industrial Park, covering an area of 228 acres, and has 18 imported IMA high-speed tea bag packaging machines from Italy. It is a company integrating R&D, production and sales, and focuses on production and management of Chinese health care functions. Advanced tea enterprise. Since its establishment, the company has developed rapidly with the concept of upright management and pragmatic management, and its business scale has continued to grow, and has obtained the export certification qualification of the health care product industry. Bishengyuan Holdings Co., Ltd. and its subsidiaries (collectively referred to as "Bishengyuan" or "Group") are high-quality suppliers of functional health tea in China, mainly engaged in the research, development, production, sales and promotion of functional health tea and medicines. For twenty years, the group has produced Bishengyuan brand Changrun Tea and Bishengyuan brand Changjing Tea (collectively known as "two teas") in accordance with the concept of "herbal health and functional teas". In recent years, the group has continued to deepen its business in the two teas and has successively launched a series of functional tea products such as Bishengyuan brand filamentary tea (collectively known as "three teas" with the two teas). The Group has started selling Laili brand Orlistat weight loss capsules since April 2015, and has been through its subsidiary Zhongshan Wanhan Pharmaceutical Co., Ltd. ("Zhongshan Wanhan") and Zhongshan Wanhan Yuanxin Pharmaceutical Research and Development Co., Ltd. ("Zhongshan Wanyuan", collectively known as "Zhongshan Wanhan Wanyuan"), develops, produces and sells Bishengyuan brand Orlistat weight loss capsules. The group's product layout extends from the weight loss health tea market to the over-the-counter drug ("OTC") market, further covering the weight loss market sector. Since its launch, Bishengyuan brand Orlistat weight loss capsules have been well received by consumers. The Group's San Tea Production Base is located in Fangshan District, Beijing. The factory and production process meet the national GMP standards. The San Tea Products have passed ISO9001, ISO22000, and HACCP system certification. The packaging equipment is a C24 type tea bag high-speed machine introduced by IMA, Italy. It is specially designed for "cotton thread sailor knot connecting tea bags and hanging tags". The inner and outer bags are formed at one time and the bag making process is automatically completed. The production workshop is fully enclosed, and the pelletizing workshop and the inner packaging workshop are clean areas of 100,000 yuan, and are temperature and humidity monitoring. The overall plan of the factory is a garden-style factory with a beautiful environment and the sanitation, technology, process, and management are all at the advanced level of the industry. The three teas in the Group are all made of natural Chinese herbal medicines and tea as raw materials, and are scientifically developed, formulated and produced. They are in need of intestinal moistening and laxative and weight management, or have been slightly disturbed in health and quality of life. Those who provide safe, effective, convenient and affordable health care products. On September 29, 2010, Bishengyuan Holdings Co., Ltd. was officially listed on the main board of the Hong Kong Stock Exchange with the stock code HK00926, marking a historic step for Bishengyuan to achieve the integration of corporate development with the international capital market. In the future, the Group will continue to deepen its development in the big health industry, and build industrial cooperation and incubation mechanisms based on the fields of "weight loss and weight management" and "intestinal moistening and laxative and gastrointestinal health", improve the industrial chain, and strive to build a big health industry. Ecological system.
Zhongshan Wanhan Pharmaceutical Co., Ltd.
Zhongshan Wanhan Pharmaceutical Co., Ltd. was founded in 2013 and is a high-tech enterprise integrating drug research and development, production and sales. It covers an area of 100 mu and has built a production and quality management system that meets the requirements of GMP and European and American drug quality management guidelines. It is a well-known domestically renowned anti-influenza drugs, eye drops, weight loss drugs and raw materials manufacturers. Have the ability to develop and produce raw materials. There are 4 multi-functional raw material production workshops and independent precision baking bags, thousands of reaction equipment; the storage facilities are complete and special chemical storage qualifications; oral solid preparations, eye drops, injections, and membranes that meet GMP requirements , ointment and liniment production workshop. The production capacity of oral solid preparations is 500 million doses/year, and the eye drops is 100 million doses/year; it has the ability to undertake CMO/CDMO business of related dosage forms; it has reliable drug quality control capabilities, equipped with LC-MS, HPLC, GC, HPIC , micro leakage sealing tester, fully automatic endotoxin measuring instrument and other advanced analytical and inspection instruments; have the ability to complete the development, verification and daily inspection of physical and chemical, instruments, microorganisms, endotoxins and aseptic methods.
Zhongshan Wanhan Pharmaceutical Co., Ltd.
Zhongshan Wanhan Pharmaceutical Co., Ltd. was founded in 2013 and is a high-tech enterprise integrating drug research and development, production and sales. It covers an area of 100 mu and has built a production and quality management system that meets the requirements of GMP and European and American drug quality management guidelines. It is a well-known domestically renowned anti-influenza drugs, eye drops, weight loss drugs and raw materials manufacturers. Have the ability to develop and produce raw materials. There are 4 multi-functional raw material production workshops and independent precision baking bags, thousands of reaction equipment; the storage facilities are complete and special chemical storage qualifications; oral solid preparations, eye drops, injections, and membranes that meet GMP requirements , ointment and liniment production workshop. The production capacity of oral solid preparations is 500 million doses/year, and the eye drops is 100 million doses/year; it has the ability to undertake CMO/CDMO business of related dosage forms; it has reliable drug quality control capabilities, equipped with LC-MS, HPLC, GC, HPIC , micro leakage sealing tester, fully automatic endotoxin measuring instrument and other advanced analytical and inspection instruments; have the ability to complete the development, verification and daily inspection of physical and chemical, instruments, microorganisms, endotoxins and aseptic methods.
Eli Lilly (Shanghai) Management Co., Ltd.
Founded in 1876, Eli Lilly was founded by Colonel Eli Lilly, who is committed to producing high-quality medicines that meet actual needs. More than a century later, Lilly continues to carry on this tradition as it continues to seek to achieve the goal of making life better for the individuals, communities and the world around it. Historical inheritance and values are the basis of the commitments made by Lilly. Lilly adheres to the belief of care and exploration, and is committed to the research and development of innovative drugs to make people all over the world live a better life. Globally, Eli Lilly’s employees continue to work to invent and bring life-changing medicines for those in need, raise awareness and management of diseases, and give back to relevant communities through charity and volunteer activities. Eli Lilly's relationship with China can be traced back to the early twentieth century. Lilly came to China in 1918 and set up its first overseas representative office in Shanghai, thus taking the pace of globalization. After many ups and downs, Lilly returned to China in 1993. For more than 20 years, Eli Lilly has focused on expanding its business in China in accordance with the concept of "rooted in China and benefiting China". Eli Lilly has about 3,400 employees in China, and its company's business has now penetrated into nearly 400 cities in China. Eli Lilly established Eli Lilly Suzhou Pharmaceutical Co., Ltd. in Suzhou, which is its wholly-owned pharmaceutical company in China. Adhere to continuous innovation and high-quality manufacturing, as long as medicines with the red Eli Lilly logo represent high quality. Eli Lilly increased its capital and expanded its production base in China twice within five years, practicing its consistent commitment to China, demonstrating Eli Lilly's firm confidence in this global large-scale pharmaceutical market in the future. In order to effectively bridge China's current innovation ecological environment, better leverage China's current favorable policy environment, promote new drug development faster, and bring new breakthrough drugs to global and Chinese patients, Eli Lilly China Innovation Cooperation Center brings the Such a mission came into being in 2018. Eli Lilly’s business principles in China are consistent with the principles globally, fully reflecting the creed of “integrity first, pursuit of excellence, and putting people first”. Eli Lilly’s purpose is to become an honest Chinese corporate citizen, and to provide high-quality medicines to the Chinese people by “rooting China and benefiting China”, saving patients’ lives and improving the quality of life of the public. Eli Lilly is committed to becoming the main strategic partner in China's healthcare field, with a far-sighted vision and giving back to society. Over the past 20 years since returning to China, Eli Lilly has devoted great enthusiasm to the development of public health and social assistance activities. At the same time, Eli Lilly has carried out various forms of mass education activities to convey disease information, popularize health knowledge, and improve the public's quality of life.
Eli Lilly (Shanghai) Management Co., Ltd.
Founded in 1876, Eli Lilly was founded by Colonel Eli Lilly, who is committed to producing high-quality medicines that meet actual needs. More than a century later, Lilly continues to carry on this tradition as it continues to seek to achieve the goal of making life better for the individuals, communities and the world around it. Historical inheritance and values are the basis of the commitments made by Lilly. Lilly adheres to the belief of care and exploration, and is committed to the research and development of innovative drugs to make people all over the world live a better life. Globally, Eli Lilly’s employees continue to work to invent and bring life-changing medicines for those in need, raise awareness and management of diseases, and give back to relevant communities through charity and volunteer activities. Eli Lilly's relationship with China can be traced back to the early twentieth century. Lilly came to China in 1918 and set up its first overseas representative office in Shanghai, thus taking the pace of globalization. After many ups and downs, Lilly returned to China in 1993. For more than 20 years, Eli Lilly has focused on expanding its business in China in accordance with the concept of "rooted in China and benefiting China". Eli Lilly has about 3,400 employees in China, and its company's business has now penetrated into nearly 400 cities in China. Eli Lilly established Eli Lilly Suzhou Pharmaceutical Co., Ltd. in Suzhou, which is its wholly-owned pharmaceutical company in China. Adhere to continuous innovation and high-quality manufacturing, as long as medicines with the red Eli Lilly logo represent high quality. Eli Lilly increased its capital and expanded its production base in China twice within five years, practicing its consistent commitment to China, demonstrating Eli Lilly's firm confidence in this global large-scale pharmaceutical market in the future. In order to effectively bridge China's current innovation ecological environment, better leverage China's current favorable policy environment, promote new drug development faster, and bring new breakthrough drugs to global and Chinese patients, Eli Lilly China Innovation Cooperation Center brings the Such a mission came into being in 2018. Eli Lilly’s business principles in China are consistent with the principles globally, fully reflecting the creed of “integrity first, pursuit of excellence, and putting people first”. Eli Lilly’s purpose is to become an honest Chinese corporate citizen, and to provide high-quality medicines to the Chinese people by “rooting China and benefiting China”, saving patients’ lives and improving the quality of life of the public. Eli Lilly is committed to becoming the main strategic partner in China's healthcare field, with a far-sighted vision and giving back to society. Over the past 20 years since returning to China, Eli Lilly has devoted great enthusiasm to the development of public health and social assistance activities. At the same time, Eli Lilly has carried out various forms of mass education activities to convey disease information, popularize health knowledge, and improve the public's quality of life.
Lunan Pharmaceutical Group Co., Ltd.
Shulja Orlistat Capsules, the orlistat raw material used is prepared by Lunan Pharmaceutical Group using an orlistat-containing preparation method. It is local obesity and whole body after childbirth, such as abdomen and waist. A healthy and scientific weight loss medicine for obese people. The common name of Shulga is Orlistat capsules, and its main ingredient is Orlistat. Shuerjia is a specific gastrointestinal lipase inhibitor. By directly blocking the body's absorption of fat in food, once the heat energy and fat intake are less than the consumption, the body's fat will naturally decrease, thus achieving the purpose of weight loss. Suitable for treatment for obese or overweight patients (body mass index ≥24) - beauty-loving women, business people, patients with three highs, mothers who are not breastfeeding during postpartum, and obese adolescents over 18 years old. The active ingredients of orlistat do not enter the blood circulation, do not act on the central nervous system, have fewer side effects, and will not experience dizziness, palpitations, insomnia, dry mouth, etc.
Lunan Pharmaceutical Group Co., Ltd.
Shulja Orlistat Capsules, the orlistat raw material used is prepared by Lunan Pharmaceutical Group using an orlistat-containing preparation method. It is local obesity and whole body after childbirth, such as abdomen and waist. A healthy and scientific weight loss medicine for obese people. The common name of Shulga is Orlistat capsules, and its main ingredient is Orlistat. Shuerjia is a specific gastrointestinal lipase inhibitor. By directly blocking the body's absorption of fat in food, once the heat energy and fat intake are less than the consumption, the body's fat will naturally decrease, thus achieving the purpose of weight loss. Suitable for treatment for obese or overweight patients (body mass index ≥24) - beauty-loving women, business people, patients with three highs, mothers who are not breastfeeding during postpartum, and obese adolescents over 18 years old. The active ingredients of orlistat do not enter the blood circulation, do not act on the central nervous system, have fewer side effects, and will not experience dizziness, palpitations, insomnia, dry mouth, etc.
Zeen Biotechnology Co., Ltd.
Yasu is a brand under Zhien Biotechnology Co., Ltd. (formerly Chongqing Zhien Pharmaceutical Co., Ltd.). Zhien Biotechnology Co., Ltd. was founded in 2001 and is a national high-tech enterprise. The company focuses on building a full life cycle management service system for drugs, with MAH (Drug Marketing Authorization Holder) as the core, and compliant management and key technical service capabilities in the entire process of drug research and development, manufacturing, transaction promotion, post-market research, etc. , supports the registration, marketing and commercial delivery of MAH drugs. After 20 years of development, the company has been approved to establish the "Chongqing Chiral Drug Engineering Technology Research Center", "Chongqing New Drug Design Engineering Technology Research Center", and "Chongqing Postdoctoral Research Workstation"; and jointly build the country with Chongqing University. Level "National and Local Joint Engineering Research Center for Advanced Drug Manufacturing Technology". The industrial achievements that have been formed at present include: 33 new drug certificates, 51 production approval documents, 11 foreign invention patents (including 2 in the United States, 2 in Europe, 1 in Japan, 2 in South Korea, and 1 in India), and 36 domestic invention patents . The company has created a research and development platform established by Liangjiang Drug, Liujiang Medicine and Lanjiang Medicine, and is represented by Geyi Pharmaceutical Clinical Research Center (BE/I Clinical Research Center that complies with the GCP standards of the National Medical Products Administration). To provide integrated services for drug research and development and drug clinical research. A CMO industrial service platform has been built with Changshou raw materials production base and Jinfeng preparation production base as the core. The Changshou raw materials production base covers an area of 82,000 square meters, and the Jinfeng Preparation production base covers an area of 49,000 square meters. The raw material drug production capacity exceeds 100 tons, and the preparation production line covers dosage forms such as constant-release and slow-release capsules, granules, tablets, etc. The company focuses on the research, development, production and sales of drugs such as metabolic system, central nervous system, respiratory system and cardiovascular system, and has multiple domestic first imitation and exclusive products and multiple Sino-US dual-report varieties. Among them, the total sales of orlistat capsule brands such as "Yasu" exceeded 1.4 billion yuan; Donepipirazine hydrochloride tablets are the winning products of the second batch of national medical insurance procurement, and other varieties (methanestone granules, ropinirole hydrochloride tablets) It also has good market performance. At the same time, the company actively expands the integration of new retail and traditional retail industries. In order to accelerate the layout in the entire pharmaceutical industry, the company has built three major support platforms with the main line of "International Advanced Manufacturing Capacity + Non-profit Research and Evaluation Organization + Biomedical Transformation Special Fund" and actively promotes international leading enterprises in the field of biopharmaceuticals. The manufacturing of antibody and recombinant protein drugs jointly developed by South Korea's BINEX company, the biotechnology training center and pilot platform jointly developed by Cytiva Situfan (formerly GE Medical Life Sciences Division), and the research and development and pharmaceuticals introduced in cooperation with outstanding domestic companies. Technology, etc., help realize the industrialization of high-value pharmaceutical products such as large-molecular drugs, cell therapy and modern Chinese medicine represented by antibody drugs and new vaccines in Chongqing, and quickly improve the high-level development of the local pharmaceutical industry. Wood is straight from the heart, and planting medicine is the benevolence. Zhien Biological will focus on building a full life cycle management service system for drugs, with MAH as the core, provide more professional, more efficient and more trustworthy services, create better drugs, and meet the public's pursuit of life and health.
Zeen Biotechnology Co., Ltd.
Yasu is a brand under Zhien Biotechnology Co., Ltd. (formerly Chongqing Zhien Pharmaceutical Co., Ltd.). Zhien Biotechnology Co., Ltd. was founded in 2001 and is a national high-tech enterprise. The company focuses on building a full life cycle management service system for drugs, with MAH (Drug Marketing Authorization Holder) as the core, and compliant management and key technical service capabilities in the entire process of drug research and development, manufacturing, transaction promotion, post-market research, etc. , supports the registration, marketing and commercial delivery of MAH drugs. After 20 years of development, the company has been approved to establish the "Chongqing Chiral Drug Engineering Technology Research Center", "Chongqing New Drug Design Engineering Technology Research Center", and "Chongqing Postdoctoral Research Workstation"; and jointly build the country with Chongqing University. Level "National and Local Joint Engineering Research Center for Advanced Drug Manufacturing Technology". The industrial achievements that have been formed at present include: 33 new drug certificates, 51 production approval documents, 11 foreign invention patents (including 2 in the United States, 2 in Europe, 1 in Japan, 2 in South Korea, and 1 in India), and 36 domestic invention patents . The company has created a research and development platform established by Liangjiang Drug, Liujiang Medicine and Lanjiang Medicine, and is represented by Geyi Pharmaceutical Clinical Research Center (BE/I Clinical Research Center that complies with the GCP standards of the National Medical Products Administration). To provide integrated services for drug research and development and drug clinical research. A CMO industrial service platform has been built with Changshou raw materials production base and Jinfeng preparation production base as the core. The Changshou raw materials production base covers an area of 82,000 square meters, and the Jinfeng Preparation production base covers an area of 49,000 square meters. The raw material drug production capacity exceeds 100 tons, and the preparation production line covers dosage forms such as constant-release and slow-release capsules, granules, tablets, etc. The company focuses on the research, development, production and sales of drugs such as metabolic system, central nervous system, respiratory system and cardiovascular system, and has multiple domestic first imitation and exclusive products and multiple Sino-US dual-report varieties. Among them, the total sales of orlistat capsule brands such as "Yasu" exceeded 1.4 billion yuan; Donepipirazine hydrochloride tablets are the winning products of the second batch of national medical insurance procurement, and other varieties (methanestone granules, ropinirole hydrochloride tablets) It also has good market performance. At the same time, the company actively expands the integration of new retail and traditional retail industries. In order to accelerate the layout in the entire pharmaceutical industry, the company has built three major support platforms with the main line of "International Advanced Manufacturing Capacity + Non-profit Research and Evaluation Organization + Biomedical Transformation Special Fund" and actively promotes international leading enterprises in the field of biopharmaceuticals. The manufacturing of antibody and recombinant protein drugs jointly developed by South Korea's BINEX company, the biotechnology training center and pilot platform jointly developed by Cytiva Situfan (formerly GE Medical Life Sciences Division), and the research and development and pharmaceuticals introduced in cooperation with outstanding domestic companies. Technology, etc., help realize the industrialization of high-value pharmaceutical products such as large-molecular drugs, cell therapy and modern Chinese medicine represented by antibody drugs and new vaccines in Chongqing, and quickly improve the high-level development of the local pharmaceutical industry. Wood is straight from the heart, and planting medicine is the benevolence. Zhien Biological will focus on building a full life cycle management service system for drugs, with MAH as the core, provide more professional, more efficient and more trustworthy services, create better drugs, and meet the public's pursuit of life and health.
Zhejiang Hisun Pharmaceutical Co., Ltd.
Yiningman orlistat tablets, the main ingredient is orlistat, suitable for the treatment of obese or overweight patients (body mass index ≥24), specification 0.12g, approval number: National Drug Approval No. H20100089. 【Tao】 1. It is prohibited for pregnant women. 2. Contraindicated for patients who are allergic to orlistat or any of the ingredients in a pharmaceutical preparation. 3. It is contraindicated for patients with chronic malabsorption syndrome and cholestatic disease. 4. It is prohibited for organic obesity (such as hypothyroidism). Zhejiang Haizheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Haizheng Pharmaceutical") was founded in 1956 and was listed on the A-share market in 2000. In 2012, it established Haizheng Pfizer Pharmaceutical Co., Ltd. in the field of branded generic drugs with Pfizer. Haizheng Pharmaceutical is headquartered in Taizhou, Zhejiang, Fuyang, Hangzhou, and Rudong, Jiangsu, and other places. It has developed core cities such as Beijing and Shanghai with intensive knowledge, talents and technology, and has formed chemical drugs. There are three major business groups: Biopharmaceuticals and Big Health. The marketing network covers more than 70 countries and regions around the world and has developed into a "pharmaceutical industry group" composed of raw materials, preparations, biological drugs, innovative drugs and commercial circulation businesses. Haizheng Pharmaceutical has a nationally recognized enterprise technology center, a provincial academician workstation, a provincial postdoctoral research workstation with independent recruitment qualifications, and a full-time R&D personnel. The research and development and production of drug treatment areas covers anti-tumor, anti-infection, and cardiovascular treatment. , endocrine, immunosuppression, anti-depression, orthopedics, etc. Haizheng Pharmaceutical provides multi-faceted support for the growth and entrepreneurship of its employees, and has a broad stage in all fields of marketing, R&D, technology, manufacturing and management. Haizheng Pharmaceutical provides employees with various work, training and learning opportunities at home and abroad, so that employees can share the success of the company as they grow. Be persistent in drug innovation and achieve the dream of health and longevity. Haizheng looks forward to working hand in hand with you to strive to realize Haizheng's globalization and sustainable development of Chinese medicine.
Zhejiang Hisun Pharmaceutical Co., Ltd.
Yiningman orlistat tablets, the main ingredient is orlistat, suitable for the treatment of obese or overweight patients (body mass index ≥24), specification 0.12g, approval number: National Drug Approval No. H20100089. 【Tao】 1. It is prohibited for pregnant women. 2. Contraindicated for patients who are allergic to orlistat or any of the ingredients in a pharmaceutical preparation. 3. It is contraindicated for patients with chronic malabsorption syndrome and cholestatic disease. 4. It is prohibited for organic obesity (such as hypothyroidism). Zhejiang Haizheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Haizheng Pharmaceutical") was founded in 1956 and was listed on the A-share market in 2000. In 2012, it established Haizheng Pfizer Pharmaceutical Co., Ltd. in the field of branded generic drugs with Pfizer. Haizheng Pharmaceutical is headquartered in Taizhou, Zhejiang, Fuyang, Hangzhou, and Rudong, Jiangsu, and other places. It has developed core cities such as Beijing and Shanghai with intensive knowledge, talents and technology, and has formed chemical drugs. There are three major business groups: Biopharmaceuticals and Big Health. The marketing network covers more than 70 countries and regions around the world and has developed into a "pharmaceutical industry group" composed of raw materials, preparations, biological drugs, innovative drugs and commercial circulation businesses. Haizheng Pharmaceutical has a nationally recognized enterprise technology center, a provincial academician workstation, a provincial postdoctoral research workstation with independent recruitment qualifications, and a full-time R&D personnel. The research and development and production of drug treatment areas covers anti-tumor, anti-infection, and cardiovascular treatment. , endocrine, immunosuppression, anti-depression, orthopedics, etc. Haizheng Pharmaceutical provides multi-faceted support for the growth and entrepreneurship of its employees, and has a broad stage in all fields of marketing, R&D, technology, manufacturing and management. Haizheng Pharmaceutical provides employees with various work, training and learning opportunities at home and abroad, so that employees can share the success of the company as they grow. Be persistent in drug innovation and achieve the dream of health and longevity. Haizheng looks forward to working hand in hand with you to strive to realize Haizheng's globalization and sustainable development of Chinese medicine.
Chongqing Watson Pharmaceutical Co., Ltd.
Huasen Pharmaceutical (stock code: 002907) is a national key high-tech enterprise integrating scientific research, production and sales, and a large comprehensive modern pharmaceutical enterprise in China. It has established a post-Bo Scientific Research Workstation and Chongqing City Haizhi workstation. Huasen Pharmaceuticals is owned by Beijing Huasen Inno Biotechnology Co., Ltd., Beijing Bosen Biotechnology Co., Ltd., Pharscin US Inc. (Huasen Pharmaceutical (US) Co., Ltd.), Chongqing Huasen Biotechnology Co., Ltd., Chongqing Huasen Pharmaceutical Co., Ltd., Chongqing Huasen Pharmacy Retail Chain Co., Ltd. Huasen Pharmaceuticals is based on the concept of "technology-led, innovation-driven, inheriting the essence, adhering to the truth and innovation", and creating high-quality products that are "specialized, refined, special and new". Currently, the company has 77 drug approval documents, including Chinese patent medicines, chemical raw materials and preparations, and has 1 US ANDA equity product, including 56 drugs in the national "medical insurance" catalog, 49 national drug standards, and 72 patents. It undertakes 120 scientific and technological research and development projects in various national, provincial and municipal ministries and commissions. In terms of innovative drug research and development, Watson Pharmaceuticals (Wassen Inno) has promoted a differentiated R&D pipeline and is committed to building an innovative drug research and development team with an international perspective, focusing on small-molecular drugs in the fields of tumors, tumor immunity and self-invigorating diseases. Development has already had 4 independently developed innovative drugs in tumor category 1.1, and its potential indications cover tumor immunity and lung cancer, breast cancer, colorectal cancer, pancreatic cancer and other solid tumors; it has been built to develop multiple innovative drugs. platform. In terms of external cooperation in innovative drugs, we cooperated with the scientific research achievement conversion platform of the scientist team of the National Key Laboratory of Biotherapy of Sichuan University to invest in the establishment of Chengdu Aoru Pharmaceutical Co., Ltd., a technology platform based on artificial intelligence drug discovery dedicated to small molecule targeting New drug research and development company for innovative drugs; cooperate with Zhongke Computing Technology Western Research Institute and Beijing Zheyuan Technology Co., Ltd. to screen new tumor drug targets, drug candidate development, translational medicine research, preclinical and clinical development, registration and application, market approval and other work to create a new height for biomedical innovation. In terms of generic drugs, Chinese patent medicines and special medical food research and development, the company has implemented the R&D strategy of "excellent production costs, fast R&D speed, and high technical barriers", and has laid out the digestive system, mental nervous system, respiratory system, tumor, and postoperative reduction. In the fields of heavy and heavy industry, through the continuous accumulation of project experience, eight national R&D technologies have been established, including “Raw Materials Engineering Transformation Research Platform, Industrial Pharmaceutical Prescription Design and Process Amplification Research Platform, CMC (Chemical and Quality Control) and Impurity Quantitative Analysis Research Platform”. The company has established a testing center in the construction of common R&D platforms, which has passed the CNAS certification. Huasen Pharmaceutical takes "developing good medicines, healthy human beings, and achieving employees" as its corporate mission, upholds the values of "integrity, diligence, gratitude, learning, teamwork, innovation", and uses solid steps to "make good Chinese medicine and go to the world" The Huasen Dream has been striving forever, contributing to the construction of the Chengdu-Chongqing Twin Cities Economic Circle and contributing to the realization of the Chinese dream of the great rejuvenation of the Chinese nation.
Chongqing Watson Pharmaceutical Co., Ltd.
Huasen Pharmaceutical (stock code: 002907) is a national key high-tech enterprise integrating scientific research, production and sales, and a large comprehensive modern pharmaceutical enterprise in China. It has established a post-Bo Scientific Research Workstation and Chongqing City Haizhi workstation. Huasen Pharmaceuticals is owned by Beijing Huasen Inno Biotechnology Co., Ltd., Beijing Bosen Biotechnology Co., Ltd., Pharscin US Inc. (Huasen Pharmaceutical (US) Co., Ltd.), Chongqing Huasen Biotechnology Co., Ltd., Chongqing Huasen Pharmaceutical Co., Ltd., Chongqing Huasen Pharmacy Retail Chain Co., Ltd. Huasen Pharmaceuticals is based on the concept of "technology-led, innovation-driven, inheriting the essence, adhering to the truth and innovation", and creating high-quality products that are "specialized, refined, special and new". Currently, the company has 77 drug approval documents, including Chinese patent medicines, chemical raw materials and preparations, and has 1 US ANDA equity product, including 56 drugs in the national "medical insurance" catalog, 49 national drug standards, and 72 patents. It undertakes 120 scientific and technological research and development projects in various national, provincial and municipal ministries and commissions. In terms of innovative drug research and development, Watson Pharmaceuticals (Wassen Inno) has promoted a differentiated R&D pipeline and is committed to building an innovative drug research and development team with an international perspective, focusing on small-molecular drugs in the fields of tumors, tumor immunity and self-invigorating diseases. Development has already had 4 independently developed innovative drugs in tumor category 1.1, and its potential indications cover tumor immunity and lung cancer, breast cancer, colorectal cancer, pancreatic cancer and other solid tumors; it has been built to develop multiple innovative drugs. platform. In terms of external cooperation in innovative drugs, we cooperated with the scientific research achievement conversion platform of the scientist team of the National Key Laboratory of Biotherapy of Sichuan University to invest in the establishment of Chengdu Aoru Pharmaceutical Co., Ltd., a technology platform based on artificial intelligence drug discovery dedicated to small molecule targeting New drug research and development company for innovative drugs; cooperate with Zhongke Computing Technology Western Research Institute and Beijing Zheyuan Technology Co., Ltd. to screen new tumor drug targets, drug candidate development, translational medicine research, preclinical and clinical development, registration and application, market approval and other work to create a new height for biomedical innovation. In terms of generic drugs, Chinese patent medicines and special medical food research and development, the company has implemented the R&D strategy of "excellent production costs, fast R&D speed, and high technical barriers", and has laid out the digestive system, mental nervous system, respiratory system, tumor, and postoperative reduction. In the fields of heavy and heavy industry, through the continuous accumulation of project experience, eight national R&D technologies have been established, including “Raw Materials Engineering Transformation Research Platform, Industrial Pharmaceutical Prescription Design and Process Amplification Research Platform, CMC (Chemical and Quality Control) and Impurity Quantitative Analysis Research Platform”. The company has established a testing center in the construction of common R&D platforms, which has passed the CNAS certification. Huasen Pharmaceutical takes "developing good medicines, healthy human beings, and achieving employees" as its corporate mission, upholds the values of "integrity, diligence, gratitude, learning, teamwork, innovation", and uses solid steps to "make good Chinese medicine and go to the world" The Huasen Dream has been striving forever, contributing to the construction of the Chengdu-Chongqing Twin Cities Economic Circle and contributing to the realization of the Chinese dream of the great rejuvenation of the Chinese nation.
Hunan Dinuo Pharmaceutical Co., Ltd.
Hunan Dino Pharmaceutical Co., Ltd. was established in December 1997. Its predecessor originated from the Hunan Provincial Institute of Pharmaceutical Industry. It is a modern pharmaceutical enterprise integrating science, industry and trade. It has a production base of more than 70,000 square meters in Liuyang Economic and Technological Development Zone, Hunan Province, with a modern factory of nearly 30,000 square meters, and a high-end office building in Changsha City with a marketing office base of 2,000 square meters, and more than 200 provinces and cities in China and various There are offices in the area. A marketing elite team of 1,000 people is specially trained. The marketing network covers hospitals, chains, single pharmacies and clinics at all levels in China (the company's product cooperation is more than 1,000 first- and second-level businesses, more than 1,000 direct supply chains, and 1,000 There are many hospitals, more than 50,000 clinics; more than 80,000 pharmacies; the top 100 mainstream chains have cooperation.) There are more than 2,000 employees, with a total annual sales of 500 million yuan and an annual profit of 70 million yuan. With excellent product quality, and high-quality services have established Dino brand image in the field of medicine.
Hunan Dinuo Pharmaceutical Co., Ltd.
Hunan Dino Pharmaceutical Co., Ltd. was established in December 1997. Its predecessor originated from the Hunan Provincial Institute of Pharmaceutical Industry. It is a modern pharmaceutical enterprise integrating science, industry and trade. It has a production base of more than 70,000 square meters in Liuyang Economic and Technological Development Zone, Hunan Province, with a modern factory of nearly 30,000 square meters, and a high-end office building in Changsha City with a marketing office base of 2,000 square meters, and more than 200 provinces and cities in China and various There are offices in the area. A marketing elite team of 1,000 people is specially trained. The marketing network covers hospitals, chains, single pharmacies and clinics at all levels in China (the company's product cooperation is more than 1,000 first- and second-level businesses, more than 1,000 direct supply chains, and 1,000 There are many hospitals, more than 50,000 clinics; more than 80,000 pharmacies; the top 100 mainstream chains have cooperation.) There are more than 2,000 employees, with a total annual sales of 500 million yuan and an annual profit of 70 million yuan. With excellent product quality, and high-quality services have established Dino brand image in the field of medicine.
Novo Nordisk (China) Pharmaceuticals Co., Ltd.
Founded in 1923, Novo Nordisk is a world-leading biopharmaceutical company headquartered in Copenhagen, the capital of Denmark. The company's goal is to promote change to overcome diabetes and other serious chronic diseases such as obesity, rare blood diseases, endocrine disorders, etc. To achieve this goal, Novo Nordisk leads scientific breakthroughs, expands the company's access to drugs, and is committed to preventing and ultimately curing diseases. Novo Nordisk has about 47,000 employees in 80 countries and regions around the world, providing products and services to more than 168 countries and regions around the world. For nearly 100 years, Novo Nordisk has been committed to addressing unmet medical needs in patients with severe chronic diseases through innovative drugs and drug delivery devices such as insulin pens. Today, Novo Nordisk's treatment options benefit millions of people with diabetes, obesity, rare blood and endocrine diseases. From laboratories to factories, we continue to discover and develop innovative biopharmaceuticals that provide them to patients around the world and improve access to drugs. Novo Nordisk focuses on serious chronic diseases that affect hundreds of millions of people around the world, responding to the world's most urgent health challenges. Novo Nordisk combines innovation with operational excellence capabilities and collaborates with patients and partners to transform bold ideas into drugs that save lives or prevent disease. Novo Nordisk makes long-term investments in innovative treatment options and technologies, including stem cell therapy, to continue to advance the development of medical devices and digital health solutions.
Novo Nordisk (China) Pharmaceuticals Co., Ltd.
Founded in 1923, Novo Nordisk is a world-leading biopharmaceutical company headquartered in Copenhagen, the capital of Denmark. The company's goal is to promote change to overcome diabetes and other serious chronic diseases such as obesity, rare blood diseases, endocrine disorders, etc. To achieve this goal, Novo Nordisk leads scientific breakthroughs, expands the company's access to drugs, and is committed to preventing and ultimately curing diseases. Novo Nordisk has about 47,000 employees in 80 countries and regions around the world, providing products and services to more than 168 countries and regions around the world. For nearly 100 years, Novo Nordisk has been committed to addressing unmet medical needs in patients with severe chronic diseases through innovative drugs and drug delivery devices such as insulin pens. Today, Novo Nordisk's treatment options benefit millions of people with diabetes, obesity, rare blood and endocrine diseases. From laboratories to factories, we continue to discover and develop innovative biopharmaceuticals that provide them to patients around the world and improve access to drugs. Novo Nordisk focuses on serious chronic diseases that affect hundreds of millions of people around the world, responding to the world's most urgent health challenges. Novo Nordisk combines innovation with operational excellence capabilities and collaborates with patients and partners to transform bold ideas into drugs that save lives or prevent disease. Novo Nordisk makes long-term investments in innovative treatment options and technologies, including stem cell therapy, to continue to advance the development of medical devices and digital health solutions.
Zhi'en Biotechnology Co., Ltd.
Ellie® Orlistat Capsules advocate a healthy weight loss concept, reducing oil absorption from the source and controlling energy intake. Zhien Bio was established in April 2001. The company has R&D bases, raw materials and preparation production bases and sales companies in various places. It is a national high-tech enterprise integrating pharmaceutical R&D, manufacturing, sales and health services. The company focuses on building a full life cycle management service system for drugs. Through the "product (service) delivery + commodity trading service", it uses MAH (pharmaceutical marketing authorization holder) as the core, providing R&D, manufacturing, transaction promotion, and post-marketing. Research and other drugs throughout the life cycle. The company insists on using innovative development as the driving force and builds core R&D capabilities. The R&D team has more than 20 core experts with more than ten years of R&D management experience in pharmaceutical companies at home and abroad, and more than 80% of them are undergraduate or above. The products under research cover different fields such as chemical drugs, biological drugs and traditional Chinese medicine. There are more than 50 projects under research, with key technologies for asymmetric catalytic synthesis, synthetic biology (enzyme catalytic technology), slow-release preparation technology, and liposome preparations. technology and other core technologies. Accumulated 46 production approvals, 117 domestic and foreign patents, and 666 authorized trademarks have been obtained. Obtained national qualifications such as the National Enterprise Technology Center, the National Specialized and New "Little Giant" Enterprise, the National Intellectual Property Demonstration Enterprise, the National and Local Joint Engineering Research Center for Advanced Drug Manufacturing Technology; obtained the Chongqing Postdoctoral Research Station and Chongqing New Drug Design Project Technology Research Center, Chongqing Chiral Drug Engineering Technology Research Center, Innovation Drug and Advanced Drug Manufacturing Technology Engineering Research Center and many other municipal honors. The company's key products have been listed include Orlistat capsules (weight loss drugs), donepezil hydrochloride tablets (Alzheimer's drug), ropinirole hydrochloride tablets (Parkinson's disease drug), and quetiapine fumarate sustained release Tablets (antipsychotic drugs), totansetron hydrochloride injection (chemotherapy, radiotherapy drugs). Among them, the company's flagship product Orlistat uses the world's first asymmetric catalytic full synthesis technology, and its core patented technology won the second prize of the National Technical Invention. The company is currently the world's largest supplier of orlistat raw materials and preparations, and has a production base that has achieved full synthesis of raw materials and has achieved domestic production earlier in China. Focusing on the pharmaceutical industry service chain, the company has invested in the construction of multiple research and development and manufacturing bases such as chemical raw materials, chemical preparations, biological drugs, traditional Chinese medicine, and vaccines, and has advanced transformation and manufacturing capabilities in chemical drugs, traditional Chinese medicine, and biological drugs.
Zhi'en Biotechnology Co., Ltd.
Ellie® Orlistat Capsules advocate a healthy weight loss concept, reducing oil absorption from the source and controlling energy intake. Zhien Bio was established in April 2001. The company has R&D bases, raw materials and preparation production bases and sales companies in various places. It is a national high-tech enterprise integrating pharmaceutical R&D, manufacturing, sales and health services. The company focuses on building a full life cycle management service system for drugs. Through the "product (service) delivery + commodity trading service", it uses MAH (pharmaceutical marketing authorization holder) as the core, providing R&D, manufacturing, transaction promotion, and post-marketing. Research and other drugs throughout the life cycle. The company insists on using innovative development as the driving force and builds core R&D capabilities. The R&D team has more than 20 core experts with more than ten years of R&D management experience in pharmaceutical companies at home and abroad, and more than 80% of them are undergraduate or above. The products under research cover different fields such as chemical drugs, biological drugs and traditional Chinese medicine. There are more than 50 projects under research, with key technologies for asymmetric catalytic synthesis, synthetic biology (enzyme catalytic technology), slow-release preparation technology, and liposome preparations. technology and other core technologies. Accumulated 46 production approvals, 117 domestic and foreign patents, and 666 authorized trademarks have been obtained. Obtained national qualifications such as the National Enterprise Technology Center, the National Specialized and New "Little Giant" Enterprise, the National Intellectual Property Demonstration Enterprise, the National and Local Joint Engineering Research Center for Advanced Drug Manufacturing Technology; obtained the Chongqing Postdoctoral Research Station and Chongqing New Drug Design Project Technology Research Center, Chongqing Chiral Drug Engineering Technology Research Center, Innovation Drug and Advanced Drug Manufacturing Technology Engineering Research Center and many other municipal honors. The company's key products have been listed include Orlistat capsules (weight loss drugs), donepezil hydrochloride tablets (Alzheimer's drug), ropinirole hydrochloride tablets (Parkinson's disease drug), and quetiapine fumarate sustained release Tablets (antipsychotic drugs), totansetron hydrochloride injection (chemotherapy, radiotherapy drugs). Among them, the company's flagship product Orlistat uses the world's first asymmetric catalytic full synthesis technology, and its core patented technology won the second prize of the National Technical Invention. The company is currently the world's largest supplier of orlistat raw materials and preparations, and has a production base that has achieved full synthesis of raw materials and has achieved domestic production earlier in China. Focusing on the pharmaceutical industry service chain, the company has invested in the construction of multiple research and development and manufacturing bases such as chemical raw materials, chemical preparations, biological drugs, traditional Chinese medicine, and vaccines, and has advanced transformation and manufacturing capabilities in chemical drugs, traditional Chinese medicine, and biological drugs.
Huadong Medicine Co., Ltd.
Huadong Pharmaceutical Co., Ltd. (stock code: 000963) was founded in 1993 and is headquartered in Hangzhou, Zhejiang. It was listed on the Shenzhen Stock Exchange in December 1999. After more than 20 years of development, the company's business covers the entire pharmaceutical industry chain, with the pharmaceutical industry as the main focus. At the same time, it expands the pharmaceutical business, medical beauty industry and industrial microbiology business, and has developed into a large-scale comprehensive medicine integrating pharmaceutical research and development, production and distribution. Listed companies. The company's pharmaceutical industry is deeply engaged in the research and development, production and sales of specialty, chronic disease drugs and special drugs, and has formed a complete pharmaceutical production, manufacturing and quality research system, and has formed a field mainly in chronic kidney disease, transplant immunity, endocrine, digestive system and other fields. The core product pipeline has multiple first-line clinical drugs with market advantages in China. At the same time, through independent development, external introduction, project cooperation and other methods, it focuses on innovative drugs and high technical barriers in the three core therapeutic areas of tumor, endocrine and autoimmune. Generic drugs are being researched and released. The company continues to carry out international product registration, international certification, consistency evaluation and other work, and continues to achieve results. It has formed an international pharmaceutical industry system and maintains R&D and product cooperation relationships with many international innovative R&D companies. The company's pharmaceutical business has four major business segments: Chinese and Western medicine, medical devices, medicinal materials, ginseng and antlers, and health industry, covering pharmaceutical wholesale, pharmaceutical retail, third-party pharmaceutical flows featuring cold chain, medical e-commerce, hospital value-added services and special health Industries, further expand the fields of product agency and market expansion, the traditional Chinese medicine industry has built a full industrial chain from base planting to decoction preparation, automated decoction, and functional products, providing customers with comprehensive solutions. The company's medical beauty business adheres to the strategy of "global operation layout, dual circulation operation development". With an international perspective, through forward-looking layout, it has more than 30 products in the field of non-invasive and minimally invasive medical beauty, of which the products have been listed at home and abroad. More than 20 models, more than 10 innovative products under research around the world, the product portfolio covers non-surgical mainstream medical beauty fields such as facial filling, facial cleaning, thread burial, skin management, body shaping, hair removal, and private repair, and has formed a comprehensive The product cluster, product quantity and coverage are among the top in the industry. Sinclair, a wholly-owned subsidiary, is the company's global medical beauty operation platform. It is headquartered in the UK and has production bases in the Netherlands, France, the United States, Switzerland and Bulgaria. The company has been deeply engaged in the field of industrial microbiology for more than 40 years, has a deep industrial foundation and industrial transformation capabilities, and has successfully developed and manufactured a variety of microbial drugs, built a key technical system for the research and development and production of microbial products, and the scale and technology of existing microbial fermentation products. The level is at the advanced level in the industry. It has three microbial R&D platforms: China-US East China, Hunda Bio and Hunyi Bio, five industrial bases: Hangzhou Xiangfuqiao, Qiantang New District, Jiangsu Jiuyang, Meiqi Health and Meihua Hi-Tech. It currently has a large-scale scale in Zhejiang Province. The fermentation monomer workshop and the industry's advanced microbial drug production capacity, the R&D capacity covers all stages of microbial engineering technology such as strain construction, metabolic regulation, separation and purification, enzyme catalysis, and synthesis modification. It has formed microbial project research and development, pilot and commercialization. A complete manufacturing system guaranteed by production, engineering and public system.
Huadong Medicine Co., Ltd.
Huadong Pharmaceutical Co., Ltd. (stock code: 000963) was founded in 1993 and is headquartered in Hangzhou, Zhejiang. It was listed on the Shenzhen Stock Exchange in December 1999. After more than 20 years of development, the company's business covers the entire pharmaceutical industry chain, with the pharmaceutical industry as the main focus. At the same time, it expands the pharmaceutical business, medical beauty industry and industrial microbiology business, and has developed into a large-scale comprehensive medicine integrating pharmaceutical research and development, production and distribution. Listed companies. The company's pharmaceutical industry is deeply engaged in the research and development, production and sales of specialty, chronic disease drugs and special drugs, and has formed a complete pharmaceutical production, manufacturing and quality research system, and has formed a field mainly in chronic kidney disease, transplant immunity, endocrine, digestive system and other fields. The core product pipeline has multiple first-line clinical drugs with market advantages in China. At the same time, through independent development, external introduction, project cooperation and other methods, it focuses on innovative drugs and high technical barriers in the three core therapeutic areas of tumor, endocrine and autoimmune. Generic drugs are being researched and released. The company continues to carry out international product registration, international certification, consistency evaluation and other work, and continues to achieve results. It has formed an international pharmaceutical industry system and maintains R&D and product cooperation relationships with many international innovative R&D companies. The company's pharmaceutical business has four major business segments: Chinese and Western medicine, medical devices, medicinal materials, ginseng and antlers, and health industry, covering pharmaceutical wholesale, pharmaceutical retail, third-party pharmaceutical flows featuring cold chain, medical e-commerce, hospital value-added services and special health Industries, further expand the fields of product agency and market expansion, the traditional Chinese medicine industry has built a full industrial chain from base planting to decoction preparation, automated decoction, and functional products, providing customers with comprehensive solutions. The company's medical beauty business adheres to the strategy of "global operation layout, dual circulation operation development". With an international perspective, through forward-looking layout, it has more than 30 products in the field of non-invasive and minimally invasive medical beauty, of which the products have been listed at home and abroad. More than 20 models, more than 10 innovative products under research around the world, the product portfolio covers non-surgical mainstream medical beauty fields such as facial filling, facial cleaning, thread burial, skin management, body shaping, hair removal, and private repair, and has formed a comprehensive The product cluster, product quantity and coverage are among the top in the industry. Sinclair, a wholly-owned subsidiary, is the company's global medical beauty operation platform. It is headquartered in the UK and has production bases in the Netherlands, France, the United States, Switzerland and Bulgaria. The company has been deeply engaged in the field of industrial microbiology for more than 40 years, has a deep industrial foundation and industrial transformation capabilities, and has successfully developed and manufactured a variety of microbial drugs, built a key technical system for the research and development and production of microbial products, and the scale and technology of existing microbial fermentation products. The level is at the advanced level in the industry. It has three microbial R&D platforms: China-US East China, Hunda Bio and Hunyi Bio, five industrial bases: Hangzhou Xiangfuqiao, Qiantang New District, Jiangsu Jiuyang, Meiqi Health and Meihua Hi-Tech. It currently has a large-scale scale in Zhejiang Province. The fermentation monomer workshop and the industry's advanced microbial drug production capacity, the R&D capacity covers all stages of microbial engineering technology such as strain construction, metabolic regulation, separation and purification, enzyme catalysis, and synthesis modification. It has formed microbial project research and development, pilot and commercialization. A complete manufacturing system guaranteed by production, engineering and public system.
Hunan Mingrui Pharmaceutical Co., Ltd.
Hunan Mingrui Pharmaceutical Co., Ltd. was established in August 1992 and is located at No. 221 Fuqian Road, Liuyang Economic and Technological Development Zone, Hunan Province with a registered capital of 258 million yuan. Mingrui Pharmaceuticals has the enterprise mission of "scientific and technological innovation to serve human health" and has now developed into an innovation-driven pharmaceutical enterprise specializing in the research, development, production and sales of chemical raw materials, chemical preparations and Chinese patent medicines. The company currently has three wholly-owned subsidiaries, namely Beijing Huarui Dingxin Technology Co., Ltd. (R&D Center), Hunan Bencao Pharmaceutical Co., Ltd. (Chinese patent medicine production base), and Hunan Mingrui Western Pharmaceutical Co., Ltd. (Sales Company ), after years of steady development, it has grown into a key enterprise in the pharmaceutical industry in Hunan Province. Mingrui Pharmaceutical has always adhered to the development concept of "talent, quality, and innovation", adhered to the business policy of "product first, quality first, and customer first", and is market-oriented, talent-centered, and innovation-driven to create core competition. We will strive for progress and be brave in innovation, and continuously achieve new leaps and breakthroughs in enterprise development.
Hunan Mingrui Pharmaceutical Co., Ltd.
Hunan Mingrui Pharmaceutical Co., Ltd. was established in August 1992 and is located at No. 221 Fuqian Road, Liuyang Economic and Technological Development Zone, Hunan Province with a registered capital of 258 million yuan. Mingrui Pharmaceuticals has the enterprise mission of "scientific and technological innovation to serve human health" and has now developed into an innovation-driven pharmaceutical enterprise specializing in the research, development, production and sales of chemical raw materials, chemical preparations and Chinese patent medicines. The company currently has three wholly-owned subsidiaries, namely Beijing Huarui Dingxin Technology Co., Ltd. (R&D Center), Hunan Bencao Pharmaceutical Co., Ltd. (Chinese patent medicine production base), and Hunan Mingrui Western Pharmaceutical Co., Ltd. (Sales Company ), after years of steady development, it has grown into a key enterprise in the pharmaceutical industry in Hunan Province. Mingrui Pharmaceutical has always adhered to the development concept of "talent, quality, and innovation", adhered to the business policy of "product first, quality first, and customer first", and is market-oriented, talent-centered, and innovation-driven to create core competition. We will strive for progress and be brave in innovation, and continuously achieve new leaps and breakthroughs in enterprise development.
Shanghai Renhui Biopharmaceutical Co., Ltd.
FITUS benaglutide injection, combined with diet control and exercise, is used for weight management in adults. Renhui Bio is an innovative biopharmaceutical company founded in 1999, focusing on the research, development and commercialization of innovative biopharmaceuticals in the field of chronic diseases. After more than 20 years of dedicated exploration, Renhui Bio has gained innovative drug results in the fields of diabetes and weight loss, and has laid a wealth of R&D pipelines in the fields of endocrine and cardiovascular diseases. Since its establishment, the company has successively signed scientific research projects such as the "Eleventh Five-Year Plan" and "13th Five-Year Plan" major new drug creation projects, major projects for strategic emerging industries in Shanghai, and major scientific and technological research projects in Shanghai. In the field of diabetes, the innovative biological drug benaglutide injection was independently developed. In the field of weight loss, the full-human GLP-1 receptor agonist Feisumei® was approved in July 2023. Renhui Bio takes continuous innovation as the cornerstone of its development and has built multiple core technology platforms in drug discovery, CMC, clinical research, etc. In the field of genetic engineering tandem technology, the company's technical patents have been authorized by more than a dozen countries including the United States, Europe, Japan, and the middle school. Based on this, the company has formed solid technical accumulation in all process links of polypeptide and protein drug preparation technology. . At present, the company has applied for 30 invention patents in China and obtained 18 authorizations; applied for 105 international invention patents, and obtained 61 authorizations. Renhui Bio's Shanghai Production Base was completed in 2009 and the expansion project was approved in 2019. It has a world-class customized system and equipment, fully automated regulation of the production process, and the data can be traced throughout the process. With advanced quality management concepts, we penetrate into every link of daily management, and strive for excellence for every patient. Patients are the first and science is the basis. Renhui Bio's vision is to become a more clinically valuable enterprise in the field of innovative drugs, and to serve the desire of chronic disease patients for life and health with enthusiasm.
Shanghai Renhui Biopharmaceutical Co., Ltd.
FITUS benaglutide injection, combined with diet control and exercise, is used for weight management in adults. Renhui Bio is an innovative biopharmaceutical company founded in 1999, focusing on the research, development and commercialization of innovative biopharmaceuticals in the field of chronic diseases. After more than 20 years of dedicated exploration, Renhui Bio has gained innovative drug results in the fields of diabetes and weight loss, and has laid a wealth of R&D pipelines in the fields of endocrine and cardiovascular diseases. Since its establishment, the company has successively signed scientific research projects such as the "Eleventh Five-Year Plan" and "13th Five-Year Plan" major new drug creation projects, major projects for strategic emerging industries in Shanghai, and major scientific and technological research projects in Shanghai. In the field of diabetes, the innovative biological drug benaglutide injection was independently developed. In the field of weight loss, the full-human GLP-1 receptor agonist Feisumei® was approved in July 2023. Renhui Bio takes continuous innovation as the cornerstone of its development and has built multiple core technology platforms in drug discovery, CMC, clinical research, etc. In the field of genetic engineering tandem technology, the company's technical patents have been authorized by more than a dozen countries including the United States, Europe, Japan, and the middle school. Based on this, the company has formed solid technical accumulation in all process links of polypeptide and protein drug preparation technology. . At present, the company has applied for 30 invention patents in China and obtained 18 authorizations; applied for 105 international invention patents, and obtained 61 authorizations. Renhui Bio's Shanghai Production Base was completed in 2009 and the expansion project was approved in 2019. It has a world-class customized system and equipment, fully automated regulation of the production process, and the data can be traced throughout the process. With advanced quality management concepts, we penetrate into every link of daily management, and strive for excellence for every patient. Patients are the first and science is the basis. Renhui Bio's vision is to become a more clinically valuable enterprise in the field of innovative drugs, and to serve the desire of chronic disease patients for life and health with enthusiasm.
Bontril is a prescription weight loss medication that acts as a stimulant to suppress appetite and increase energy levels.
Validus Pharmaceuticals
Bontril is a prescription weight loss medication that acts as a stimulant to suppress appetite and increase energy levels.
Garcinia Cambogia Select is a dietary supplement that uses the extract of the Garcinia Cambogia fruit to support weight loss and appetite control.
Healths Harmony
Garcinia Cambogia Select is a dietary supplement that uses the extract of the Garcinia Cambogia fruit to support weight loss and appetite control.
Various generic manufacturers
Orlistat is the active ingredient in Xenical and Alli, available as a generic weight loss medication that reduces fat absorption.
Various generic manufacturers
Orlistat is the active ingredient in Xenical and Alli, available as a generic weight loss medication that reduces fat absorption.
Iovate Health Sciences International Inc.
Hydroxycut is a well-known weight loss supplement that uses a blend of natural ingredients to enhance fat burning and energy levels.
Iovate Health Sciences International Inc.
Hydroxycut is a well-known weight loss supplement that uses a blend of natural ingredients to enhance fat burning and energy levels.
PhenQ is a popular dietary supplement that combines multiple weight loss benefits, including fat burning, appetite suppression, and energy boosting.
Wolfson Berg Limited
PhenQ is a popular dietary supplement that combines multiple weight loss benefits, including fat burning, appetite suppression, and energy boosting.
Xenical is a prescription weight loss medication that contains orlistat, which helps reduce fat absorption in the intestines.
Roche
Xenical is a prescription weight loss medication that contains orlistat, which helps reduce fat absorption in the intestines.
Alli is an FDA-approved over-the-counter weight loss pill that works by preventing the absorption of some of the fat you eat.
GlaxoSmithKline
Alli is an FDA-approved over-the-counter weight loss pill that works by preventing the absorption of some of the fat you eat.
